Akari Therapeutics plc ADS (AKTX)

About AKTX

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer typ…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

www.akaritx.com/

Fundamentals

1-day range

$8.8$11.08

Market cap

$12.88M

P/E (trailing)

Infinity

P/E (forward)

-0.76

EPS (trailing)

$-0.01

Dividend yield

—

Beta

1.43

Avg. volume

72.5K

Forecasts

2 analyst ratings

Akari Therapeutics plc ADS Competitors

Chosen by industry and closest market cap.

• AKTX

  Akari Therapeutics plc ADS

  $11.03

  ▲ 22.42%
  Market cap $12.88MP/E Infinity
  $3.02$49.6
• COCP

  Cocrystal Pharma Inc. Common Stock

  $1.11

  ▼ 2.63%
  Market cap $12.96MP/E —
  $0.76$2.67
• PHIO

  Phio Pharmaceuticals Corp. Common Stock

  $1.13

  ▲ 0.45%
  Market cap $11.97MP/E —
  $0.8127$4.19
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  Benzinga · 8/26/2026
• Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
  benzinga · 8/18/2026
• Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy
  Benzinga · 8/18/2026
• Akari Therapeutics Announces Preclinical Data Of AKTX-101 Shows Anti-Tumor Activity Throughout Multiple Clinically Relevant Urothelial Cancer Preclinical Models
  Benzinga · 8/18/2026
• Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
  Benzinga · 8/13/2026
• Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
  Benzinga · 7/31/2026

• Kameel D. Farag · July 16, 2026 · Grant

  1.1K @ $11.5
• Samir Rashmikant Patel · July 7, 2026 · Option Exercise

  5.8K @ $0.0004
• Samir Rashmikant Patel · July 7, 2026 · Option Exercise

  15.5K @ $0.0004
• Samir Rashmikant Patel · July 7, 2026 · Option Exercise

  1.2K @ $8
• Kameel D. Farag · June 24, 2026 · Grant

  1.0K @ $13
• Kameel D. Farag · June 24, 2026 · Grant

  7.4K @ $3.74
• Kameel D. Farag · June 24, 2026 · Grant

  3.7K @ $3.49
• Kameel D. Farag · June 24, 2026 · Grant

  2.5K @ $5.12
• Kameel D. Farag · June 24, 2026 · Grant

  1.6K @ $8.28
• Kameel D. Farag · June 24, 2026 · Grant

  1.4K @ $9.32
• Kameel D. Farag · June 24, 2026 · Grant

  1.2K @ $10.02
• Abizer Gaslightwala · June 24, 2026 · Grant

  15.6K
• Abizer Gaslightwala · June 24, 2026 · Grant

  5.5K

Institutional Ownership

March 31, 2026

Total shares held

59.7K

Total value held

$307.3K

Institutional holders

6